Representing Fearless andUndaunted Innovators.
The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
News and Featured Insights
Leading Matters
Client Highlights
Wilson Sonsini Advises SandboxAQ on Agreement with the U.S. Department of Commerce for $500 Million CHIPS R&D Award
On June 17, 2026, SandboxAQ announced a definitive agreement with the U.S. Department of Commerce's CHIPS Research and Development Office for a $500 million award to address one of the most urgent challenges in American manufacturing: the foreign control of critical materials and chemistries that are essential to semiconductor manufacturing. Wilson Sonsini Goodrich & Rosati advised SandboxAQ on the transaction.
Client Highlights
Wilson Sonsini Advises Clair Health on $11.6 Million Seed Round
On June 17, 2026, San Francisco-based Clair Health, a wellness wearable start-up designed to monitor hormones, announced an $11.6 million seed round led by Khosla Ventures, with participation from a16z speedrun, Brydge Club, TreeHub, Cartan Capital, AGI House, Insiders VC, and Anne Wojcicki. Wilson Sonsini Goodrich & Rosati advised Clair Health on the transaction.
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Client Highlights
Wilson Sonsini Advises Energy Dome on Collaboration Agreement with Salt River Project
On June 15, 2026, Energy Dome, a leading provider of innovative capacity solutions for utilities and AI infrastructure, and Salt River Project (SRP), a not-for-profit public power utility serving the greater Phoenix metropolitan area, announced an agreement to add a 19-megawatt, 10-hour carbon dioxide-based battery system to the grid. The project is part of Google and SRP’s innovative collaboration to accelerate deployment of non-lithium-ion long-duration energy storage technologies that support reliability, affordability, and sustainability. Wilson Sonsini Goodrich & Rosati advised Energy Dome on the transaction.
Client Highlights
Firm Advises 4E Therapeutics on Acquisition by Eli Lilly
On June 16, 2026, 4E Therapeutics, an Austin-based neuroscience company developing next-generation treatments for chronic pain, announced that it has been acquired by Eli Lilly and Company. Wilson Sonsini Goodrich & Rosati advised 4E Therapeutics on the transaction.
Client Highlights
Wilson Sonsini Advises Beren Therapeutics P.B.C. on $300 Million Financing, Including Equity and Debt and Royalty Facilities
On June 10, 2026, Beren Therapeutics P.B.C., a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, announced it has secured $300 million in combined financing. The financing consists of:
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.